|Provectus' Abstract on Liver Cancer Accepted for Poster Presentation; Ocata Announces Positive Results in Treating Macular Degeneration|
|By Josh Gee|
|Thursday, 30 April 2015 19:33|
Below is a look at some of the headlines for companies that made news in the healthcare sector on April 30, 2015.
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT), a clinical-stage oncology and dermatology biopharmaceutical company, announced today that the European Society for Medical Oncology (ESMO) has accepted the Company’s abstract, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver," for poster presentation at the ESMO 17th World Congress on Gastrointestinal Cancer.
The conference runs July 1-4, 2015, and is being held at The International Convention Center of Barcelona, in Barcelona, Spain. The Company will post the presentation on its website at www.pvct.com at the time of the presentation.
The abstract, number P-116, will be available online on June 24, 2015. Provectus will provide more details about the presentation and conference as they become available.
About the European Society for Medical Oncology -- The European Society for Medical Oncology (ESMO) is the leading European professional organization committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment and care.
ESMO's mission is to advance cancer care and cure through fostering and disseminating good science that leads to better medicine and determines best practice. ESMO's scientific journal, Annals of Oncology, ranks among the top clinical oncology journals worldwide. ESMO events are the meeting place in Europe for medical oncologists to update their knowledge, to network and to exchange ideas.
Ocata Therapeutics, Inc. (NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced that a study has been published that includes top-line, positive results in Asian patients who were treated with Ocata’s proprietary RPE cells, manufactured using its DeltaCell™ Technology.
These new data support previously reported positive long-term safety and signs of visual improvement, as presented in The Lancet of October 15th, 2014. The Korean study published online in Stem Cell Reports features twelve months of post-transplant follow-up data from four Asian patients; two with Stargardt’s macular degeneration (SMD) and two with dry age-related macular degeneration (AMD).
“The results of this study conducted by CHA Biotech in Asian patients support the findings published in The Lancet in October 2014 and further underscores our leadership in regenerative ophthalmology,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “The safe treatment of a total of forty two patients across multiple studies with this novel therapeutic approach in geographically distinct patient populations is encouraging. We look forward to the planned initiation of our comprehensive Phase 2 safety study in dry AMD and a pivotal study in SMD, two disabling diseases where there is no cure available today.”
In this study there was no evidence of adverse proliferation, tumorigenic behavior, ectopic tissue formation, or other serious safety issues related to the transplanted cells. Although designed as a safety study, visual acuity improved 9–19 letters in three patients and remained stable (+1 letter) in one patient. Vision was measured using the widely accepted standard for visual acuity testing, the Early Treatment Diabetic Retinopathy Study visual acuity exam.
Robert Lanza, M.D., Chief Scientific Officer of Ocata Therapeutics and co-senior author of the paper, commented, “These results support the potential safety and efficacy of hESC-derived cells in Asian patients and provides further evidence that hESC-derived cells could serve as a potentially safe new source for regenerative medicine.”
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that the Company's first quarter 2015 financial results will be released on Thursday, May 7, 2015.
Cellular Biomedicine Group Inc. (Nasdaq:CBMG), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today announced that it intends to vigorously defend against the claims made in a putative securities class action lawsuit filed against the company and two of its officers in the United States District Court for the Northern District of California.
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the quarter ended March 31, 2015 and provided an update on recent corporate developments.
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that it will report first quarter 2015 financial results after market close on Thursday, May 7, 2015.
CombiMatrix Corporation (Nasdaq:CBMX) announced today that it will release its first quarter 2015 financial results on Thursday, May 7, 2015. Results will be released after the close of trading on that day.
Geron Corporation (Nasdaq:GERN) today reported financial results and recent events for the first quarter ended March 31, 2015.
Greatbatch, Inc. (NYSE:GB), today announced results for its first quarter ended April 3, 2015.
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the appointment, effective May 1, 2015, of Keith Valentine as Chief Executive Officer of SeaSpine Holdings Corporation, which will be an independent, publicly traded company following the completion of its spin-off from Integra.
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today reported its financial results for the first quarter ending March 31, 2015.
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), today announced the completion of the previously announced transition of the CEO role from Ron Bentsur to Greg Madison.
MannKind Corporation (Nasdaq:MNKD) will release its 2015 first quarter financial results on Thursday, May 7, 2015 and its management will host a conference call to discuss the first quarter financial results and other Company developments at 9:00 AM (Eastern Time) on May 8, 2015.
Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its first quarter 2015 financial and operating results after the close of U.S. financial markets on Thursday, May 7, 2015.
Nuo Therapeutics, Inc. (OTCQX:NUOT) a pioneer in biodynamic therapies, today announced that David Jorden, current Executive Chairman of the Company's Board of Directors, has been appointed Acting Chief Financial Officer officially effective May 24, 2015 but will assume some roles immediately.
Spark Therapeutics (Nasdaq:ONCE) today announced that it will host a conference call on Wednesday, May 6, 2015 at 8:30 a.m. Eastern to report corporate and financial results for the three months ended March 31, 2015.
StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the first quarter 2015, after the market close on Tuesday, May 5.